clinical trial showed that Rotarix was as efficacious in Japan as in other industrialized countries, it is expected that the annual number of rotavirus hospitalizations will be reduced to between 1000-3000, and that outpatient visits will be reduced to 200,000. The universal rotavirus immunization program with Rotarix was calculated to be at the threshold of being cost-effective, even from the healthcare perspective, and it was highly cost-effective from the societal perspective, assuming that Rotarix is co-administered with other childhood vaccines. While Rotarix contains only a single G1P [8] human rotavirus, the postlicensure studies in Brazil showed that Rotarix provided a 75%-85% protective efficacy against severe dehydrating diarrhea or hospitalizations due to fully-heterotypic G2P [4] strains. While postlicensure studies detected a small and finite risk of intussusception associated with the administration of Rotarix, the authors conclude that Rotarix is safe to administer to infants between 6-12 weeks of age for the first dose and by 24 weeks of age for the second dose. However, the authors strongly discourage the delayed administration of the first dose between 13-20 weeks of age, which is allowed without any warning. Given the high incidence of naturally-occurring intussusception in Japan (185 cases per 100,000 children/year among children less than 1 year of age), this should prevent pediatricians and parents from having ill-perceptions of Rotarix being associated with an increased number of temporally-associated intussusception, and fully appreciate the benefit
INTRODUCTION
Acute diarrhea is the leading cause of childhood morbidity and mortality worldwide, accounting for approximately 15% of deaths occurring in children less than 5 years of age. 1 
27,28
The birth cohort in Japan is approximately 1 million and the information required is the number of children who will be hospitalized due to rotavirus-associated diarrhea when the cohort is followed for 5 years. Only a few studies are available in Japan, and it was estimated that there were 790,000 outpatient visits, 29 27,000-78,000 hospitalizations, [30] [31] [32] Germany, Italy, Spain, Sweden, and the UK (the REVEAL study), the incidence ranged from a minimum of 2.9 per 1000 children/year in the UK to a maximum of 9.9 per 1000 children/year in Belgium, with a median of 6.5 per 1000 children/year in Spain. 33, 34 If the rotavirus vaccine is as efficacious in ).
The WHO recommends that the first dose should be administered at age 6-15 weeks. 41 In Australia, the first dose of Rotarix is scheduled to be given to infants between 6-14 weeks of age (Figure 1) . 42 In the US, the Advisory Committee on Immunization Practices (ACIP) revised its recommendation in 2009 to extend the maximum age for the first dose to be 14 weeks and 6 days, 43 but it clearly stated that vaccination should not be initiated for infants after 15 weeks and 0 days (Figure 1 ).
In Europe, the European Medicines Agency 44 states that both doses should preferably be administered before 16 weeks of age, meaning that the first dose is to be given to infants at Figure 1 . The age period during which the first and the second dose of Rotarix are to be administered according to the package insert distributed in Japan. The first dose may start at 6 weeks of age but before 20 weeks of age, and the second dose may start at 10 weeks of age and end before 24 weeks of age. In Europe, the upper limit of the first dose is 12 weeks, while in the US and Australia it is 14 weeks. As the first dose of Rotarix is allowed to be given to infants between 13-20 weeks of age in Japan (the area highlighted in green), a concern arises that there will be an increased number of Rotarix recipients who develop intussusception by chance alone in the first week after the first dose. 
Failed Administration (Regurgitation)
The Rotarix package insert states that a single replacement dose may be given at the same vaccination visit in the event that the infant spits out or regurgitates most of the vaccine dose. 35 The ACIP does not recommend re-dosing after regurgitation of any amount on the basis of the absence of data on the benefits or risks with re-dosing. 43 From a practical perspective, who should pay the cost of re-dosing may also be an issue.
Concomitant Vaccine Administration
In countries where Rotarix is given as part of the routine immunization schedule, such as in the US, Rotarix is administered together with other childhood vaccines, including d i p h t h e r i a -t e t a n u s -a c e l l u l a r p e r t u s s i s 
TWO KEY ISSUES RELATING TO THE ROTARIX INTRODUCTION IN JAPAN
Lastly, the authors will conclude this review by addressing the two important issues. These issues fall on the specific area of rotavirus research where the authors believe that they have expert views; whether Rotarix is effective in preventing severe diarrhea caused by fully heterotypic G2P [4] rotavirus strains and whether Rotarix is safe with respect to intussusception.
The first issue is about a persisting concern derived from the fact that Rotarix is a vaccine containing only a single human G1P [8] strain, RIX4414. The guiding principle for the development of a single-strain human rotavirus vaccine was that the induction of protective immunity does not entirely depend on neutralizing antibodies specific to either G or P serotype, but more on factors that mediate heterotypic immunity. [52] [53] [54] [55] In a large clinical trial in Latin America, and later in Europe, Rotarix was shown to be effective in preventing severe rotavirus diarrhea caused by partially heterotypic G3P [8] , G4P [8] , and G9P [8] strains, as well as fully-homotypic G1P [8] strains. 56, 57 Since fully-heterotypic G2P [4] strains were infrequent during these clinical trials, protective efficacy appeared less convincing, with wide 95% CIs. Soon after the introduction of Rotarix into the universal immunization schedule in Brazil, Gurgel et al. 58 and Nakagomi et al. 59 noticed a high predominance of G2P [4] strains, although there was also a simultaneous marked decrease in the detection rate of rotavirus. 59 While these studies suggested a shift in the predominantly circulating strains to G2P [4] 
